Incyte Swings to $3.60/Share Loss but Beats on Revenue, Tops Lowered Bar
INCY sits 31% above its 52-week low of $88.2.
Summary
Incyte posted a Q3 adjusted loss of $3.60 a share, better than the $3.85 loss analysts expected, on revenue of $1.56 billion that rose 14% and beat the $1.47 billion consensus. The GAAP picture is ugly: a $784.8 million quarterly loss, or $3.86 a share, versus $2.26 of EPS a year ago. The beat is against a bar that was cut hard — the mean estimate fell about 38.2% over three months and eight analysts revised lower in the last 30 days — so the quality of the surprise is thin. This lands alongside this morning's raise of full-year 2026 net sales guidance to $5.21-$5.30 billion from $5.13-$5.26 billion, which is the more important number for the thesis. Shares are down 3.7% this quarter but up 18.3% year to date, and the median price target of $130 sits about 10.1% above the last close of $116.87.
At the time of this announcement, INCY was trading at $115.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.4B. The 52-week trading range was $88.20 to $132.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.